Moderna Will Join Nasdaq-100 Index on October 9

The biotech firm replaces Warner Bros. Discovery following a 541% surge in stock value this year.

Updated on Oct. 2, 2026 in Biotech

Moderna Will Join Nasdaq-100 Index on October 9

Live Poll

Is now a good time for you to invest in high-growth, speculative biotech stocks?

Moderna will enter the Nasdaq-100 index before the market opens on October 9, 2026. The move follows a significant valuation increase driven by clinical trial results for the company's personalized cancer vaccine.

Why it matters

Moderna's index inclusion signals the rising market influence of biotech firms leveraging clinical data to drive valuation. This momentum has triggered increased retail investor interest in other development-stage life science companies as they track comparable growth milestones.

Moderna shares exceeded $200 in late September 2026 following positive interim Phase 3 melanoma trial results. The company's 541% year-to-date stock gain significantly outperformed the benchmarks of the index it is set to enter.

The players

Moderna

A biotechnology company specializing in mRNA therapeutics and vaccines that has scaled rapidly following the clinical development of its cancer vaccine portfolio.

ImmunityBio

A clinical-stage immunotherapy firm focused on developing cell and gene therapies, currently seeing 92% year-over-year revenue growth.

Sellas Life Sciences

A biopharmaceutical company developing novel cancer immunotherapies, including the Galinpepimut-S treatment currently in Phase 3 testing.

Warner Bros. Discovery

A media and entertainment conglomerate currently holding a position in the Nasdaq-100 index.

The details

Moderna's shift to the Nasdaq-100 index is primarily attributed to its market capitalization growth fueled by its pipeline of mRNA-based personalized cancer vaccines. These therapies work by identifying unique tumor mutations in a patient to generate a tailored immune response, effectively training the body to target malignant cells. Meanwhile, the Regal trial, a Phase 3 study evaluating the drug Galinpepimut-S, currently sits at 78 recorded deaths against a threshold of 80 required for final analysis.

Q2 2026: ImmunityBio recorded $50.7 million in net product revenue.
August 2026: Moderna released interim Phase 3 melanoma trial results.
Late September 2026: Moderna share price exceeded $200.
October 9, 2026: Moderna replaces Warner Bros. Discovery in Nasdaq-100.
January 6, 2027: Expected FDA decision on Anktiva label expansion.

The Tech Race

Moderna's entry into the Nasdaq-100 marks a significant shift in the index's composition, favoring high-growth biotech valuations over legacy sectors. This transition follows a broader trend where mRNA-based clinical milestones have dictated stock performance and market index hierarchy.

Retail investors may see increased volatility in smaller biotech stocks like Sellas Life Sciences and ImmunityBio as they are frequently compared to Moderna's valuation trajectory. Future portfolio shifts in institutional funds that track the Nasdaq-100 will begin once the October 9, 2026, rebalancing takes effect.

The takeaway

Moderna's index inclusion validates the market's current premium on biotech firms demonstrating successful clinical vaccine data. Investors should track the upcoming January 6, 2027, FDA decision for Anktiva as a potential catalyst for further sector movement.

What happens next

The industry is awaiting the final analysis of the Regal trial for Galinpepimut-S, which triggers once 80 deaths are recorded. Additionally, an FDA decision regarding a label expansion for Anktiva is expected by January 6, 2027.